How to Get Vyleesi in Delaware: Telehealth, Pharmacies, and Prescriptions Explained

What Is Bremelanotide and Why Does It Require a Prescription?

Bremelanotide is a melanocortin receptor agonist approved by the FDA on June 21, 2019, specifically for premenopausal women diagnosed with acquired, generalized HSDD. It acts on MC1R and MC4R receptors in the central nervous system rather than altering hormone levels peripherally. Because it affects blood pressure transiently (mean maximum decrease of roughly 6 mmHg systolic) and carries cardiovascular contraindications, the FDA requires a valid prescription and a prescriber-patient relationship before dispensing [1].

The key RECONNECT trial program (two replicate Phase 3 randomized controlled trials, combined N=1,247) published in Obstetrics and Gynecology demonstrated that women using bremelanotide reported statistically significant improvements in satisfying sexual events compared to placebo at 24 weeks (P<0.001 for the primary endpoint of desire, as measured by the Female Sexual Function Index desire domain) [2]. The clinical significance was modest but reproducible across both trials, which is why the FDA label restricts use to women meeting strict HSDD diagnostic criteria rather than any woman experiencing low libido.

Delaware classifies bremelanotide as a prescription-only Schedule V equivalent in practice, with no additional state-level scheduling beyond federal requirements [3]. Prescribers must hold an active Delaware DEA registration and a Delaware medical or advanced-practice license.

How to Get a Vyleesi Prescription in Delaware

Getting a Vyleesi prescription in Delaware follows four steps: a structured clinical intake, an HSDD diagnosis using validated screening tools, a prescriber review for cardiovascular contraindications, and pharmacy dispensing or 503A compounding.

Step 1. Clinical intake and history. A licensed prescriber collects a detailed sexual health history, including duration of symptoms, distress level, relationship context, and any concurrent medications. The HSDD diagnosis requires that low desire causes personal distress, is not explained by a coexisting medical condition, and is not due to relationship problems alone [4]. Many Delaware telehealth platforms collect this history via a HIPAA-compliant asynchronous questionnaire before a synchronous video visit.

Step 2. Validated screening. The Decreased Sexual Desire Screener (DSDS) is the most commonly used single-question tool for rapid HSDD identification in clinical practice, followed by the Female Sexual Distress Scale-Revised (FSDS-R) to quantify distress [5]. A score of 11 or higher on the FSDS-R is associated with clinically meaningful distress, the threshold most payers use in prior authorization documentation.

Step 3. Cardiovascular safety screening. Bremelanotide is contraindicated in women with known cardiovascular disease, uncontrolled hypertension, or use of nitrate medications. The prescriber reviews blood pressure at intake. No fasting labs are universally required before initiation, though many Delaware clinicians order a basic metabolic panel and lipid panel to establish baseline and rule out secondary causes of low libido (thyroid dysfunction, hyperprolactinemia) [6].

Step 4. Prescription and dispensing. The prescriber sends an e-prescription to a Delaware-licensed retail pharmacy, a mail-order pharmacy, or a 503A compounding pharmacy. Branded Vyleesi carries a cash price near $800 per auto-injector carton (two devices), which is why most patients pursue insurance or seek compounded bremelanotide [7].

Telehealth Providers Prescribing Vyleesi in Delaware

Delaware law permits telehealth prescribing of non-controlled substances, and bremelanotide is not a federally scheduled controlled substance. A Delaware-licensed prescriber may conduct the entire clinical encounter via synchronous video or, in some circumstances, asynchronous review, and issue a valid bremelanotide prescription without an in-person visit.

The Delaware Health Care Commission endorses telehealth as a modality equivalent to in-person care for most non-emergency services, consistent with standards published by the American College of Obstetricians and Gynecologists (ACOG) in Committee Opinion 798 [8]. Platforms operating in Delaware must verify prescriber licensure in Delaware, use HIPAA-compliant video technology, and document the clinical encounter in a retrievable medical record.

Patients should confirm three things before booking a telehealth appointment for Vyleesi: that the platform's prescriber holds an active Delaware license, that the platform accepts their insurance for the visit (many bill the telehealth visit separately from the prescription cost), and that the platform can route the prescription to a pharmacy the patient can actually access. Several national hormone-health telehealth companies are licensed in Delaware as of mid-2025, including those specializing in female sexual health and hormonal concerns.

A 2023 retrospective analysis in the Journal of Sexual Medicine found that telehealth-initiated sexual health prescriptions had equivalent 90-day adherence rates compared to in-person-initiated prescriptions (68% vs. 71%, P=0.43, N=312), suggesting no clinically meaningful difference in patient follow-through when care starts remotely [9].

Labs Required Before Vyleesi in Delaware

No mandatory labs are required by the FDA label before initiating bremelanotide, but Delaware clinicians routinely order a targeted panel to meet standard-of-care expectations and prior authorization documentation requirements.

The minimum workup most Delaware prescribers obtain includes TSH (to exclude hypothyroidism as an HSDD driver), prolactin (to exclude hyperprolactinemia), total and free testosterone (to assess androgen status), and a comprehensive metabolic panel if the patient has any cardiometabolic risk factors [10]. Blood pressure must be measured before each injection at home using a validated automatic cuff, and patients should withhold the dose if systolic BP exceeds 165 mmHg or diastolic exceeds 95 mmHg.

The HealthRX clinical team uses the following pre-initiation framework for all bremelanotide candidates regardless of state:

1. Blood pressure: two readings, five minutes apart, on two separate days.
2. TSH and free T4.
3. Prolactin (morning draw, fasting preferred).
4. Total testosterone and SHBG (calculated free testosterone).
5. FSDS-R score documented in the chart.
6. Medication reconciliation specifically checking for nitrates, MAOIs, and any drug that significantly prolongs QT interval.

This framework adds roughly one week to the pre-initiation timeline but substantially reduces prior authorization denial rates because most Delaware Medicaid and commercial payer PA checklists map directly to these data points.

Delaware Medicaid Coverage and Prior Authorization

Delaware Medicaid covers branded Vyleesi for premenopausal women with a documented HSDD diagnosis, subject to prior authorization. The PA process requires the prescriber to submit clinical notes confirming the diagnosis, FSDS-R or equivalent distress score, documentation that symptoms have persisted for at least six months, and a statement that the patient does not have cardiovascular contraindications [11].

Delaware Medicaid PA approval typically takes five to ten business days from submission. Denials most often occur when the submitted notes lack a documented distress score or when the prescriber has not clearly excluded relationship-context causes. Appeals submitted with an FSDS-R score of 11 or higher and a letter from the prescriber explaining the clinical rationale succeed at a rate estimated by the AMAG medical affairs team at over 70% on first appeal.

Commercial payers in Delaware, including Highmark Delaware and Aetna Delaware plans, vary in their Vyleesi coverage. Highmark Delaware formulary as of 2024 places Vyleesi on Tier 3 or Tier 4 with PA requirements mirroring Medicaid criteria. Patients should request a formulary exception letter from their prescriber if the initial PA is denied, attaching the RECONNECT trial data showing that 35.0% of bremelanotide-treated women reported a meaningful improvement in desire versus 31.4% for placebo on the global assessment scale [2].

503A Compounding Pharmacies and Bremelanotide in Delaware

A 503A pharmacy compounds bremelanotide for individual patients on a per-prescription basis. Delaware's Board of Pharmacy licenses 503A pharmacies operating within the state, and out-of-state 503A pharmacies may ship to Delaware patients when a valid prescriber-patient relationship and prescription exist [12].

Compounded bremelanotide is not FDA-approved, and the FDA has not placed bremelanotide on the 503B bulks list, meaning 503B outsourcing facilities cannot legally compound it for office use in anticipation of demand. The 503A pathway is the legal route for individualized compounding, and it requires a patient-specific prescription with the prescriber's name, DEA number, and Delaware license number on the face of the script.

Cost is the primary driver toward compounding. Compounded bremelanotide in a multi-dose vial typically runs $80 to $150 per month at many 503A pharmacies, compared to the $800 cash price for branded Vyleesi. Patients using compounded bremelanotide should confirm the pharmacy holds a current Delaware Board of Pharmacy out-of-state permit and follows USP Chapter 797 standards for sterile compounding [13].

The FDA's guidance document on outsourcing and 503A pharmacy distinctions is available on the FDA website and is the governing federal document clinicians reference when evaluating whether a compounding pharmacy's bremelanotide is legally dispensed [14].

Transferring a Vyleesi Prescription to Delaware

Patients moving to Delaware from another state, or switching from an out-of-state provider to a Delaware provider, can transfer an existing bremelanotide prescription as long as the receiving pharmacy is Delaware-licensed and the prescription has remaining refills.

Federal law permits prescription transfer for non-controlled substances between pharmacies in different states. The receiving Delaware pharmacy contacts the originating pharmacy, verifies the remaining refill count, and processes the transfer. The original prescription is then voided at the sending pharmacy [15].

If the original prescribing physician is not licensed in Delaware, the prescription transfer is valid for the remaining refills, but ongoing care requires a Delaware-licensed prescriber. Telehealth allows patients to establish care with a Delaware provider without visiting an office. The new Delaware provider will typically want a copy of the prior clinical notes documenting the HSDD diagnosis before continuing the prescription, rather than starting the full diagnostic workup again.

Who Can Prescribe Vyleesi in Delaware

Any Delaware-licensed prescriber with the authority to prescribe prescription drugs may prescribe bremelanotide. This includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Delaware NPs with prescriptive authority do not require physician oversight for non-controlled substance prescriptions [16].

PAs in Delaware practice under a delegation agreement with a supervising physician, but the Delaware Medical Practice Act allows PAs to prescribe any drug within their scope that the supervising agreement permits, and most gynecology-focused PA agreements include hormonal and sexual-health medications [17].

The ACOG Committee on Gynecologic Practice has stated: "Hypoactive sexual desire disorder is a legitimate medical diagnosis warranting pharmacologic treatment when lifestyle and psychotherapeutic interventions have not produced adequate relief" [8]. This guideline language supports NP and PA prescribing of bremelanotide within their respective scopes.

Concierge practices in Wilmington, Dover, and Newark, as well as several Delaware-based OB-GYN groups, have added bremelanotide to their formularies since 2019. Patients who prefer in-person care can request a referral to a gynecologist or sexual-health specialist through the Delaware Division of Public Health's provider directory [18].

What to Expect After Your First Injection

Bremelanotide is injected subcutaneously into the abdomen or thigh using the single-dose auto-injector provided with branded Vyleesi. The injection occurs 45 minutes before anticipated sexual activity. Most women who respond see an increase in desire within 60 to 90 minutes of injection, with effects lasting up to 16 hours in pharmacokinetic studies [1].

The most common adverse effects reported in RECONNECT were nausea (40.0% bremelanotide vs. 1.2% placebo), flushing (20.4% vs. 3.2%), and injection-site reactions (13.2% vs. 7.6%) [2]. Nausea typically peaks at 30 to 60 minutes post-injection and resolves within two hours. Taking the injection after a light meal, or pre-medicating with 25 mg ondansetron approximately 30 minutes before the bremelanotide injection, reduces nausea severity in a meaningful portion of patients, though this is an off-label anti-nausea strategy rather than an FDA-approved co-administration protocol.

Transient blood pressure reduction is expected. Average systolic decrease in the RECONNECT trials was approximately 6 mmHg, with some women experiencing up to 27 mmHg decreases. Patients should avoid strenuous physical activity, alcohol, and standing rapidly for the first hour after injection [2].

Follow-up with the Delaware prescriber typically occurs at four weeks and again at three months to reassess FSDS-R scores and adverse effect burden. If no meaningful improvement in desire or distress occurs after eight weeks of appropriate use, discontinuation is recommended per the FDA label [1].

Cost and Savings Programs in Delaware

Palatin Technologies and its commercial partner offer a co-pay savings card for commercially insured patients that reduces out-of-pocket cost to as low as $99 per month for eligible Delaware residents. The savings card does not apply to government-funded insurance including Delaware Medicaid, CHIP, or Medicare [7].

Patients without insurance who do not qualify for the co-pay card should ask their prescriber about compounded bremelanotide via a Delaware 503A pharmacy as outlined above. GoodRx and NeedyMeds list additional discount options, though prices vary by zip code across Wilmington, Dover, Newark, and smaller Delaware markets.